Skip to content
Open access

Integrated management of atrial fibrillation with digital health support: a pooled analysis of individual participant data from the mAFA-II and MIRACLE-AF trials.

Aug 2026 · Cardiovascular Research · 0 citations
Medicine

TL;DR

In this pooled analysis of individual participant data from two prospective randomized trials, ABC pathway-based integrated care was associated with improved clinical outcomes in patients with AF vs. usual care, with the observed benefit primarily driven by reductions in HF/ACS-related events rather than classical AF-specific outcomes.

Abstract

Aims

Adherence with a holistic or integrated care management of atrial fibrillation (AF) based on the AF better care (ABC) pathway has been associated with improved clinical outcomes. Two prospective randomized trials (mAFA and MIRACLE-AF) have evaluated this approach. The multicentre mAFA-II trial delivered the ABC pathway via mobile health using an mAFA App, while the MIRACLE-AF trial relied on village doctors supported by telehealth in rural communities. We conducted a pooled analysis of individual participant data to assess the overall efficacy of ABC pathway-based management in patients with AF.

Methods

AND

Results

We combined patient-level data from the mAFA-II and MIRACLE-AF trials. The primary endpoint was defined as a composite of all-cause mortality, ischaemic stroke, haemorrhagic stroke, heart failure (HF), acute coronary syndrome (ACS), and major bleeding events. The secondary endpoints included individual components and two grouped outcomes: all stroke and HF/ACS. A one-stage marginal Cox proportional hazards model stratified by trial and with robust standard errors clustered at the site level was used, with adjustment for CHA2DS2-VASc and other clinically relevant baseline variables. Cumulative event rates were estimated using Kaplan-Meier methods. Subgroup and sensitivity analyses were conducted to assess the robustness of the findings. Between-trial heterogeneity was further explored using a two-stage approach, incorporating trial-level effect estimates and inverse-variance weighting. We studied 4363 patients with AF [mean age 70.3 (SD 12.8) years; 60.5% male]. During 0.8 [SD 0.4] years of follow-up, the primary endpoint occurred in 329 (7.5%). Kaplan-Meier curves demonstrated lower cumulative incidence of events in the intervention group. On multivariable mixed-effects Cox models, the intervention group demonstrated a significantly lower risk of the primary endpoint compared to the control group (adjusted hazard ratio: 0.72; 95% confidence interval: 0.56-0.93). Subgroup analyses suggested potential effect modification, whereas sensitivity analyses consistently supported the primary findings. A two-stage analysis showed directionally consistent effects across trials for the primary endpoint.

Conclusion

In this pooled individual participant data from two prospective randomized trials, ABC pathway-based integrated care was associated with improved clinical outcomes in patients with AF vs. usual care, with the observed benefit primarily driven by reductions in HF/ACS-related events rather than classical AF-specific outcomes, supporting further implementation studies and context-specific adoption in clinical practice.

Read PDF

Similar papers

Review Oct 2026

Role of Lifestyle and Risk Factor Modification Clinics in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

BACKGROUND Incidence and recurrence of atrial fibrillation (AF) are associated with several lifestyle risk factors. Lifestyle and risk factor modification (LRFM) clinics could have a role in comprehensively addressing AF from a holistic, patient-centered approach to improve clinical outcomes. METHODS We performed a s...

Yan Zhao, F. Ha, Adam J. Brown et al. · 0 citations
Open access Sep 2026

Beta-blockers after Acute Coronary Syndrome: Does atrial fibrillation change the equation? A Portuguese multicentre national registry analysis

Introduction: Beta-blockers (BB) remain a cornerstone of secondary prevention after acute coronary syndrome (ACS). However, contemporary randomized trials have questioned their routine use in patients with preserved ejection fraction, often excluding those with atrial fibrillation (AF). We aimed to evaluate the prognost...

I. Moreira, L. Azevedo, C. Carvalho et al. · 0 citations
Open access Aug 2026

The effect of integrated lifestyle modification on quality of life and cost-effectiveness in atrial fibrillation ablation - results from the POP-AF RCT.

OBJECTIVES To evaluate the impact of an integrated lifestyle intervention on quality of life and cost-effectiveness in patients undergoing catheter ablation for atrial fibrillation (AF), compared with usual care. METHODS The POP-AF trial randomized patients for their first AF ablation who had at least one modifiable...

J. Vermeer, G. V. van Steenbergen, F. Vervaat et al. · 0 citations
Sep 2026

Redefining atrial fibrillation treatment success: patient-defined goals for arrhythmia burden and health-related quality of life.

Less than half of AF patients had AF-symptom scores or arrhythmia burdens reflecting patient-defined treatment success, and factors associated with reaching patient reported outcome goals were distinct from those associated with arrhythmia burden goals.

Alexander E. Kolomaya, Brian Zenger, Michael Torre et al. · 1 citation
Open access Sep 2026

Inequalities in oral anticoagulant treatment patterns: a two-part model to estimate healthcare costs associated with atrial fibrillation.

Failure to initiate, discontinuation and cessation of OAC treatment are linked to higher costs, highlighting the relevance of sustained anticoagulation, and improving treatment initiation and persistence could reduce the economic burden of AF and improve patient outcomes.

G. Ciminata, Ryan J. Mulholland, Terry J. Quinn et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.